Head and neck cancer trial pulled before it even started
NCT ID NCT06804850
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study was designed to see if adding low-dose radiotherapy to a combination of targeted therapy (Afatinib) and immunotherapy (Tislelizumab) before surgery could improve outcomes for people with resectable head and neck cancer. The trial was withdrawn before enrolling any participants, so no data were collected.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tislelizumab (immunotherapy), Afatinib (targeted therapy), and low-dose radiotherapy
What this could lead to
If it had worked, this could have pointed toward a more effective pre-surgery treatment for head and neck cancer, potentially improving tumor shrinkage before surgery.
What could go wrong
The trial was withdrawn before any participants were enrolled, so no results are available. It is unknown whether the combination would have been safe or effective.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.